Cory Freedland

Principal, Private Equity


Cory joined Sofinnova as an Associate in 2014, and was promoted to Principal in 2015. He focuses on biopharmaceutical investments. Cory has been involved in the firm’s investments in Civitas (acquired by Acorda), NextCure, NuCana Biomed, Principia Biopharma, Spark Therapeutics (ONCE), and ZS Pharma (ZSPH, acquired by AstraZeneca).

Prior to Sofinnova, Cory was a Principal at Novo A/S. Before transitioning to life sciences finance, Cory worked as a research scientist for Roche focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases. Cory moved to investment banking after Kellogg. Before his transition to healthcare venture, he was a Vice President in the healthcare investment banking practice at Morgan Stanley where he advised on over $12 billion of strategic and financing transactions in the biopharmaceutical and life science tools/diagnostics sectors.

He received his PhD in Pharmacology from Wake Forest University School of Medicine. Cory has an MBA from the Kellogg School of Management, and holds a BA in Psychology and Religious Studies from Connecticut College.

(650) 681-8434